$PBYI News

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results

Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation

TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6

Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology (NASDAQ:PBYI) Beats Q2 Estimates, but Soft Q3 Guidance Tempers Reaction

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est

Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est